Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase (NECT-FIELD)

This study has been completed.
Sponsor:
Collaborators:
Ministry of Public Health, Democratic Republic of the Congo
Swiss Tropical & Public Health Institute
Information provided by (Responsible Party):
Drugs for Neglected Diseases
ClinicalTrials.gov Identifier:
NCT00906880
First received: May 19, 2009
Last updated: May 30, 2013
Last verified: May 2013